The monoclonal antibody trastuzumab has improved the outcomes of patients with breast
cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). However …

Human epidermal growth factor receptor 2 (HER2)-targeted therapies have revolutionized
the treatment of HER2-positive breast cancer, both in the metastatic and early stage settings …

Overexpression of human epidermal growth factor occurs in approximately 20–25% of
invasive breast cancers. This subtype of breast cancer has been associated with poor …

Because metastatic breast cancer (MBC) is incurable in most cases, the goals of treatment
are improvement in quality of life, management of symptoms, and prolonged survival. The …

Introduction: Human epidermal growth factor 2 (HER2) overexpression is present in 20% of
breast cancer patients. It is associated with more aggressive disease and worse clinical …

Introduction Patients with human epidermal growth factor receptor 2 (HER2)-positive breast
cancer have a poor prognosis. Despite proven efficacy with the standard of care …

Over the last decades, a better understanding of breast cancer heterogeneity provided tools
for a biologically based personalization of anticancer treatments. In particular, the …

Introduction Targeting the human epidermal growth factor receptor (HER) family of tyrosine
kinase receptors has proven to be effective as a therapeutic strategy for HER type 2 (HER2) …

Therapeutic antibodies have shown great promise as targeted agents in the treatment of
patients with cancer. Trastuzumab, a humanized monoclonal antibody targeting human …

The human epidermal growth factor receptor 2 gene (HER2) is overexpressed and/or
amplified in∼ 15% of breast cancer patients and was identified a quarter century ago as a …